City
Epaper

UK delays Covid jab in infected kids for three months

By IANS | Updated: November 19, 2021 19:25 IST

London, Nov 19 The UK health body has delayed the second Covid jab for children aged between 16 ...

Open in App

London, Nov 19 The UK health body has delayed the second Covid jab for children aged between 16 and 17 with infection to 12 weeks, from the earlier four weeks.

The UK Health Security Agency issued the "precautionary advisory" to prevent the small risk of heart inflammation among young kids.

"For those aged 16 to 17 who have had coronavirus (Covid-19) infection, the second vaccine dose should be given 12 weeks or more following the first vaccine dose, or 12 weeks following a positive Covid-19 test result - whichever is later," the agency said in a statement.

"This increase from 4 weeks is based on the emerging evidence from the UK and other countries, which suggests that leaving a longer interval between infection and vaccination may further reduce the already small risk of myocarditis in younger age groups," it added.

The risk of the heart problem was extremely low latest data suggests nine cases of myocarditis can be expected to be seen among children for every one million doses given, UKHSA said. Cases to date have been mild and recovered quickly with treatment.

"The Covid-19 vaccines are very safe. Based on a highly precautionary approach, we are advising a longer interval between Covid infection and vaccination for those aged under 18," said Dr Mary Ramsay, Head of Immunisations at UKHSA, in the statement

Vaccines have been available to 12 to 15-year-olds in the UK since September. So far, over half of 16 and 17-year-olds have come forward for the first dose and nearly a third of 12 to 15-year-olds.

Further, the UKHSA said the advice should not affect spread of the virus given the protection offered by natural infection. It said natural infection provided good protection against re-infection for three to six months.

Around 30 per cent of children are thought to have been infected by Covid in recent months, according to official estimates based on antibody tests.

"Young people and parents should be reassured that myocarditis is extremely rare, at whatever point they take up the vaccine, and this change has been made based on the utmost precaution," Ramsay added.

However, those aged 18 and above should still take up their vaccine offer if they are 4 weeks post a positive test. This is because they are at higher risk of the complications of Covid-19 infection, the agency said.

The advice is also not for those aged 12 to 17 in clinical at-risk groups. These individuals should still take up their vaccine offer if they are 4 weeks post a positive test and continue to receive their second dose 8 weeks after the first. This is because their individual risk of severe outcomes from Covid-19 is higher and so outweighs any benefit of delaying to 12 weeks, the advisory said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: UkhsaukLondonPremier of saAdministrative capitalUk health security agency
Open in App

Related Stories

PuneNilesh Ghaywal, Pune Gangster and Accused in Kothrud Firing Case, Flees to London

BusinessTata Motors Shares Fall After JLR Faces ₹20,000 Crore Cyberattack Erasing FY25 Profits

InternationalDonald Trump Says London Mayor Sadiq Khan Among 'Worst' in World, Claims He Blocked Him from Royal Banquet

EntertainmentAnoushka Shankar and Arijit Singh Team Up for a Special Performance in London, Sitarist Says ‘There’s more to come’

CricketENG vs SA 2nd ODI LIVE Cricket Streaming: When and Where to Watch England vs South Africa Match in India

Health Realted Stories

HealthIndia advancing towards inclusive and universal social protection: Minister

HealthPremature baby dies of measles in Canada amid national outbreak

HealthWhooping cough can be fatal in children under age 2: Study

HealthMallikarjun Kharge discharged from Bengaluru hospital after pacemaker implantation

HealthEbola outbreak in Congo shows decline but challenges remain: WHO